ResMed Inc. Chairman and CEO Michael J. Farrell filed a Form 4 on November 10, 2026, disclosing option exercises and a sale of ResMed common stock executed on November 9, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercises: Farrell exercised two tranches of stock options on November 9, 2026, acquiring 683 shares and 4,310 shares, respectively, at an exercise price of $146.34 per share.
  • Open-market sale: Farrell disposed of 4,993 shares at a weighted average price of $235.3473, with individual trades ranging from $231.7956 to $237.600, according to the filing.
  • Remaining direct holdings: Following the reported transactions, Farrell directly beneficially owned 479,803 shares of ResMed common stock.
  • Indirect holdings: The filing also reports 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust.
  • 10b5-1 plan: All transactions were conducted under a Rule 10b5-1 plan adopted October 31, 2024, as noted in the filing's explanation of responses.
  • Expiring options: The options exercised carry an expiration date of November 21, 2026, and first became exercisable November 11, 2020, vesting at 1/3 per year, according to the filing.

Farrell's November 9 Transactions: Option Exercises and Share Sale Details

According to the Form 4 filed with the SEC, Michael J. Farrell, who serves as Chairman and CEO of ResMed Inc. (NYSE:RMD), exercised two separate tranches of stock options on November 9, 2026. The first tranche covered 683 shares and the second covered 4,310 shares, both at an exercise price of $146.34. The filing notes that following those exercises, Farrell's directly held position rose sequentially to 480,486 shares and then to 484,796 shares before the subsequent sale.

On the same date, Farrell disposed of 4,993 shares, reducing his direct holdings to 479,803 shares. The filing reports that the sale was executed across multiple trades at prices ranging from $231.7956 to $237.600, with the weighted average sale price reported as $235.3473. The filing attributes all three transactions to a Rule 10b5-1 trading plan that Farrell adopted on October 31, 2024.

The options exercised had an expiration date of November 21, 2026, and first became exercisable on November 11, 2020, vesting at a rate of 1/3 per year, as stated in the filing's explanation of responses. Following the transactions, the filing records that 4,310 options in one tranche remain beneficially owned directly, while the second tranche of 683 options shows zero remaining. In addition to his direct holdings, the filing discloses 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust.

What Was Disclosed

The filing reports that ResMed's Chairman and CEO exercised options covering 4,993 total shares on November 9, 2026, and sold those shares the same day under a pre-adopted 10b5-1 plan, leaving him with 479,803 directly held shares and 2,090 indirectly held shares.